Translational Oncology Research Center

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. Melanoma 44%
3. Neoplasms 36%
4. Therapeutics 23%
5. Ipilimumab 21%
6. Bortezomib 21%
7. Survival 20%
8. Bone Marrow 18%
9. Immunotherapy 15%
10. Single-Domain Antibodies 15%
11. Dendritic Cells 15%
12. Non-Small Cell Lung Carcinoma 15%
13. T-Lymphocytes 14%
14. Nivolumab 13%
15. Plasma Cells 13%
16. Breast Neoplasms 13%
17. pembrolizumab 13%
18. Mutation 13%
19. Glioblastoma 12%
20. Progression-Free Survival 10%
21. Belgium 10%
22. Mesenchymal Stem Cells 10%
23. dabrafenib 9%
24. Drug Therapy 9%
25. Lenalidomide 9%
26. Neoplasm Metastasis 9%
27. trametinib 9%
28. Safety 9%
29. Epigenomics 9%
30. Pancreatic Neoplasms 8%
31. In Vitro Techniques 8%
32. Geriatric Assessment 8%
33. Melphalan 8%
34. Growth 8%
35. Apoptosis 8%
36. Myeloid Cells 8%
37. trimix 7%
38. Genes 7%
39. Lung Neoplasms 7%
40. Temozolomide 7%
41. quisinostat 7%
42. Pharmaceutical Preparations 7%
43. Recurrence 7%
44. Myeloid-Derived Suppressor Cells 7%
45. Drug Resistance 7%
46. ErbB Receptors 7%
47. Tumor Burden 6%
48. Axitinib 6%
49. avelumab 6%
50. Glioma 6%
51. Histone Deacetylase Inhibitors 6%
52. Mitogen-Activated Protein Kinase Kinases 6%
53. Messenger RNA 6%
54. Multicenter Studies 6%
55. Protein-Tyrosine Kinases 6%
56. Antigens 6%
57. Stem Cell Transplantation 6%
58. Radiotherapy 5%
59. Adenocarcinoma 5%
60. Bone Diseases 5%
61. Cell Line 5%
62. Colorectal Neoplasms 5%
63. Geriatrics 5%
64. Population 5%
65. Clinical Trials 5%
66. Ovarian Neoplasms 5%
67. Phase II Clinical Trials 5%
68. Cell Survival 5%
69. picropodophyllin 5%
70. Clinical Trials, Phase I 5%
71. olaparib 5%
72. Stem Cells 5%
73. Quality of Life 5%
74. Bone Marrow Cells 5%
75. Ligands 5%
76. Tumor Microenvironment 5%
77. Monoclonal Antibodies 5%